Max Healthcare Institute Limited reported a strong financial performance for the quarter and year ended March 31, 2026. The board has recommended a final dividend of ₹2 per share. Key announcements include the construction of a new 712-bed hospital in Lucknow, the shifting of the company’s registered office to Haryana, and the acquisition of a controlling stake in Kalinga Hospitals Limited, signaling a strategic push to expand the company’s footprint in Eastern India.
Annual and Quarterly Financial Performance
For the financial year ended March 31, 2026, Max Healthcare achieved significant growth. The company reported a total consolidated income of ₹8,53,607 lakh for the year, with a consolidated profit for the year of ₹1,44,241 lakh. For the Q4 (January-March) period, the company reported a total income of ₹2,19,072 lakh and a net profit of ₹34,222 lakh. Reflecting this robust performance, the Board of Directors has recommended a final dividend of ₹2 per equity share, representing 20% of the face value of ₹10.
Strategic Hospital Expansion in Lucknow
The company has officially approved the construction of Phase-I of the Max Super Specialty Hospital in Lucknow. This new facility will be located on a 5-acre land parcel and is designed to accommodate approximately 712 beds. The project is expected to be completed within 36 months following the approval of architectural drawings. With an estimated investment of ₹1,400 crore, this expansion aims to address the high demand for quality healthcare in the Uttar Pradesh region.
Acquisition and Corporate Developments
Max Healthcare continues its growth trajectory with the acquisition of a controlling stake in Kalinga Hospitals Limited. The company acquired a 58.28% equity stake in the 250-bed Bhubaneswar-based multi-specialty facility for a cash consideration of ₹29,797 lakh. Furthermore, the board has approved the shifting of the company’s registered office from Mumbai, Maharashtra to Gurugram, Haryana, subject to necessary approvals.
Leadership and Governance Updates
The company also announced the re-appointment of Mr. Anil Kumar Bhatnagar as a Non-Executive and Non-Independent Director for a three-year term, effective from October 1, 2026, through September 30, 2029. Additionally, M/s. Chandra Wadhwa & Co. has been re-appointed as the Cost Auditor for the 2026-27 financial year to audit the company’s cost records.
Source: BSE
